

**Product Name** : Ralaniten

**Synonyms** : EPI-506


**Cat No.** : M10744

**CAS Number** : 1203490-23-6

**Molecular Formula** : C<sub>21</sub>H<sub>27</sub>ClO<sub>5</sub>

**Formula Weight** : 394.89

**Chemical Name** : (2R)-3-[4-(2-[4-[(2S)-3-chloro-2-hydroxypropoxy]phenyl]propan-2-yl)phenoxy]propane-1,2-diol



**Description** : Ralaniten (EPI-506) is a novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer; AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity, and as a result, may affect a broader AR population including mutational and splice variant ARs. Prostate Cancer Phase 2 Clinical

**Pathway** : Endocrinology/Hormones

**Target** : Estrogen Receptor/ERR

**Receptor** : Estrogen Receptor/ERR

**Solubility** : —

**SMILES** : CC(C)(C1=CC=C(C(=C1)OCC(CO)O)C2=CC=C(C(=C2)OCC(CCl)O

**Storage** : (-20°C)

**Stability** : ≥ 2 years

**Reference** :

1. Antonarakis ES, et al. Oncologist. 2016 Dec;21(12):1427-1435.